Parexel experts present posters highlighting real-world evidence, clinical insights, and methodologies advancing hematology research and development.
Explore Parexel’s accepted EHA 2026 abstracts below. Connect with our authors to learn more about the data, methodologies, and implications for hematology drug development, or visit us at booth A4.01.
EHA 2026 Posters
Real-World Evidence & Clinical Outcomes
Comparative Real-World Overall Survival in Diffuse Large B-Cell Lymphoma: CAR T-Cell Therapies Versus Bispecific Antibodies
Real-World Outcomes of Sickle Cell Disease Patients Transitioning From Pediatric to Adult Care: Impact on Acute Care Utilization
ICANS After CAR-T Therapy: Persistent Cognitive but Not Psychiatric Risk - A Propensity Score-Matched Analysis
Impact of Autologous Stem Cell Transplantation Following Quadruplet Therapy (Dara-VRd) on Survival Outcomes in Multiple Myeloma: A Real-World Data Analysis
Risk of Bleeding in Mantle Cell Lymphoma Patients Treated with Covalent Bruton Tyrosine Kinase Inhibitors and Contemporary Anticoagulant or Antiplatelet Agents: Real-World Data Insights
Publications
Infections following combined therapy with a GPRC5DxCD3 bispecific antibody (talquetamab) or BCMA bispecific antibodies (elranatamab/teclistamab) and an Interleukin-6 receptor inhibitor, tocilizumab, in multiple myeloma patients
Read publication
Regulatory divergence in R/R AML: contrasting FDA and EMA approaches to real-world evidence and trial design